Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$476.27 USD

476.27
490,764

+2.99 (0.63%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $476.27 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

HOLX vs. IDXX: Which Stock Is the Better Value Option?

HOLX vs. IDXX: Which Stock Is the Better Value Option?

IDEXX OPTI Medical Gets CE Mark for RT-PCR Coronavirus Test

This test by IDEXX (IDXX) benefits from an optimized workflow and claims to deliver greater assurance of quality and accuracy.

Idexx (IDXX) Up 11.3% Since Last Earnings Report: Can It Continue?

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories

Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories

IDEXX Sees Higher Clinical Visits Despite Coronavirus Crisis

IDEXX (IDXX) notes a significant improvement in U.S. clinical visit trends across major regions.

Dump These 4 Toxic Stocks or Sell Short for Timely Profits

Identifying toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses.

IDEXX (IDXX) Q1 Earnings Top Estimates, Margins Decline

IDEXX Laboratories (IDXX) companion animal clinical visits decrease due to the impact of the coronavirus pandemic.

Idexx Laboratories (IDXX) Beats Q1 Earnings Estimates

Idexx (IDXX) delivered earnings and revenue surprises of 4.88% and -0.86%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Medical Products Stock Earnings on Apr 30: BAX, IDXX & More

The medical product companies have partially mitigated the impact of the pandemic driven by the massive adoption of COVID-19 related healthcare-support products and services.

Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth

Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?

IDEXX's (IDXX) business is likely to have benefited from few cases in which pets were found to be COVID-19 positive globally.

Coronavirus Hits S&P 500: 4 MedTech Stocks That Fared Better

Here are a few MedTech companies which have outperformed the S&P 500 index in the past two months.

IDEXX's (IDXX) CAG Arm Grows Strong on Product Launches

Product launches like Cornerstone, Neo, Animana aid IDEXX' (IDXX) CAG business.

Masimo's Latest Buyout to Boost Respiratory Product Spectrum

Masimo (MASI) expects the transaction to be neutral to 2020 earnings.

Here's Why You Should Hold Onto Baxter (BAX) Stock for Now

Baxter (BAX) issues strong guidance for the first quarter of 2020.

Varian's (VAR) ProBeam Compact Treats First Patient at UAB

Varian's (VAR) flagship ProBeam platform is seeing multiple developments of late.

HealthEquity (HQY) Q4 Earnings and Revenues Top Estimates

HealthEquity's (HQY) fiscal fourth-quarter earnings benefit from higher revenues and solid performing Service, Custodial and Interchange segments.

Baxter (BAX) Q4 Earnings Beat Estimates, Revenues In Line

Baxter's (BAX) fourth-quarter earnings benefit from higher revenues, solid segmental performance and growth in APAC.

Here's Why You Should Hold Onto Varian Medical Stock Now

Varian Medical (VAR) gains from solid prospects of its core Oncology Systems unit.

Here's Why You Should Buy Cooper Companies (COO) Stock Now

Cooper Companies (COO) lifts adjusted earnings per share view for fiscal 2020.

Cooper Companies (COO) Misses on Q1 Earnings, Lifts View

Cooper Companies (COO) gains from core CVI segment in fiscal Q1.

Nalak Das headshot

5 Must-Buy S&P 500 Large-Cap Growth Stocks at a Discount

As a result of regular market fluctuations, several growth stocks have become ultra-cheap at present, some of which have strong growth potential.

Allscripts (MDRX) Q4 Earnings and Revenues Miss Estimates

Allscripts (MDRX) fourth-quarter results gain from higher revenues along with growth in bookings. Contraction in both gross and operating margins remains a woe.

Veeva Systems (VEEV) Q4 Earnings and Revenues Beat Estimates

Veeva Systems (VEEV) gains from segmental strength in the fiscal fourth quarter.

Here's Why You Should Hold Avanos Medical (AVNS) Stock Now

Avanos (AVNS) gains from solid fourth-quarter show despite headwinds in the Acute Pain business.